InnoCare Gets Approval for Phase III Study of ICP-248 and Orelabrutinib for First-Line CLL/SLL Therapy in China
InnoCare Gets Approval for Phase III Study of ICP-248 and Orelabrutinib for First-Line CLL/SLL Therapy in China InnoCare Pharma, a prominent biopharmaceutical company focusing on the treatment of cancer and…
FDA Approves GSK’s PENMENVY, a 5-in-1 Meningococcal Vaccine for MenABCWY Protection
FDA Approves GSK’s PENMENVY, a 5-in-1 Meningococcal Vaccine for MenABCWY Protection GSK plc has announced that the U.S. Food and Drug Administration (FDA) has granted approval for PENMENVY (Meningococcal Groups…
LimmaTech Starts Phase 1 Trial for S. aureus Vaccine LBT-SA7
LimmaTech Starts Phase 1 Trial for S. aureus Vaccine LBT-SA7 LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 LimmaTech Biologics AG, a clinical-stage biotech…
EDX Medical in the UK Develops Advanced ‘Super Test’ for Prostate Cancer
Breakthrough ‘Super Test’ for Prostate Cancer Developed by EDX Medical in the UK Scientists in Cambridge have unveiled a groundbreaking new diagnostic tool, hailed as a ‘super test’ for prostate…
FDA Grants Breakthrough Status to Innate Pharma’s Lacutamab for Sézary Syndrome
FDA Grants Breakthrough Status to Innate Pharma’s Lacutamab for Sézary Syndrome Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the U.S. FDA has…
U.S. FDA Fully Approves Deciphera’s ROMVIMZA™ for TGCT Treatment
U.S. FDA Fully Approves Deciphera’s ROMVIMZA™ for TGCT Treatment Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) has announced that the U.S. Food and Drug Administration (FDA)…
Anebulo Pharmaceuticals Announces Q2 FY 2025 Financial Results and Key Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Updates Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company dedicated to developing innovative…
European Commission Approves KOSTAIVE®, the First Self-Amplifying mRNA COVID-19 Vaccine by CSL and Arcturus Therapeutics
European Commission Approves KOSTAIVE®, the First Self-Amplifying mRNA COVID-19 Vaccine Global biotechnology leader and self-amplifying mRNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) have announced that the European Commission (EC) has…
OS Therapies Initiates Commercial Manufacturing of OST-HER2 Ahead of Biologics License Application (BLA) Submission
OS Therapies Initiates Commercial-Ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Application (BLA) Filing OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company dedicated to advancing immunotherapies and targeted…
EU Approves Nemluvio® for Atopic Dermatitis & Prurigo Nodularis
Galderma (SWX:GALD) has announced that the European Commission has granted approval for Nemluvio, a groundbreaking biologic therapy, for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis within the European…
GeneDx Launches ultraRapid Whole Genome Sequencing for NICU and PICU Patients
GeneDx Introduces ultraRapid Whole Genome Sequencing for NICU and PICU Patients, Offering Actionable Results in Just 48 Hours GeneDx (Nasdaq: WGS), a leading provider of genomic insights to improve health…
Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma
Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Join Forces to Accelerate Development of…